Literature DB >> 10515675

Does the presence of postmenopausal symptoms influence susceptibility to vertebral deformity? European Vertebral Osteoporosis Study (EVOS) Group.

V Scoutellas1, T W O'Neill, M Lunt, J Reeve, A J Silman.   

Abstract

BACKGROUND: Previous reports suggest a possible increased risk of osteoporosis in those with postmenopausal symptoms. There are, however, no data from population samples, exploring the relationship between postmenopausal symptoms and vertebral osteoporosis. AIM: To determine if there is an association between self-reported postmenopausal symptoms and radiographic vertebral deformity.
METHODS: Women aged 50 years and over were recruited from population registers in 30 European centres and invited to attend for an interviewer administered questionnaire and lateral thoracic and lumbar spine radiographs. The questionnaire sought information about aspects of lifestyle, personal, medical and gynaecological history, including postmenopausal symptoms: flushing, sleep disturbance and 'other' symptoms. Radiographs were taken according to a standard protocol and evaluated morphometrically. Vertebral deformity was defined according to the McCloskey-Kanis method. Bone mineral density data were obtained in a subsample of women at both the spine and femoral neck.
RESULTS: A total of 4023 postmenopausal women, aged 50-64 years, were studied: 73% reported a history of flushing, 45% sleep disturbance and 23% 'other' symptoms, at or around their menopause. The prevalence of vertebral deformity was 8.2%. Those with postmenopausal symptoms were slightly younger and more likely to have ever taken hormone replacement therapy (HRT) than those without symptoms. After adjusting for potential confounders (age, centre, body mass index, cigarette smoking and HRT) there was no association between deformity and any of the postmenopausal symptoms: flushing (odds ratio (OR) 1.0; 95% confidence intervals (CI) 0.8, 1.3), sleep disturbance (OR 1.0; 95% CI 0.8, 1.2), 'other' symptoms (OR 0.9; 95% CI 0.7, 1.3). Amongst women who had ever taken HRT, however, those with vertebral deformity were more likely to report a history of flushing (OR 2.1; 95% CI 0.9,4.8).
CONCLUSION: A history of postmenopausal symptoms per se does not appear to be associated with increased susceptibility to vertebral osteoporosis. However, women with more severe symptoms (as suggested by their use of HRT) may be at increased risk.

Entities:  

Mesh:

Year:  1999        PMID: 10515675     DOI: 10.1016/s0378-5122(99)00025-0

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  5 in total

1.  Associations of menopausal vasomotor symptoms with fracture incidence.

Authors:  Carolyn J Crandall; Aaron Aragaki; Jane A Cauley; JoAnn E Manson; Erin LeBlanc; Robert Wallace; Jean Wactawski-Wende; Andrea LaCroix; Mary Jo O'Sullivan; Mara Vitolins; Nelson B Watts
Journal:  J Clin Endocrinol Metab       Date:  2014-12-18       Impact factor: 5.958

2.  Vasomotor symptoms in infertile premenopausal women: a hitherto unappreciated risk for low bone mineral density.

Authors:  Lubna Pal; John Norian; Gohar Zeitlian; Kris Bevilacqua; Ruth Freeman; Nanette Santoro
Journal:  Fertil Steril       Date:  2008-02-20       Impact factor: 7.329

3.  Presence of vasomotor symptoms is associated with lower bone mineral density: a longitudinal analysis.

Authors:  Carolyn J Crandall; Yan Zheng; Sybil L Crawford; Rebecca C Thurston; Ellen B Gold; Janet M Johnston; Gail A Greendale
Journal:  Menopause       Date:  2009 Mar-Apr       Impact factor: 2.953

Review 4.  Determinants of fracture risk in osteoporosis.

Authors:  Nicholas Harvey; Cyrus Cooper
Journal:  Curr Rheumatol Rep       Date:  2003-02       Impact factor: 4.686

5.  Efficacy and Safety of Kudzu Flower-Mandarin Peel on Hot Flashes and Bone Markers in Women during the Menopausal Transition: A Randomized Controlled Trial.

Authors:  Ji Eon Kim; Hyeyun Jeong; Soohee Hur; Junho Lee; Oran Kwon
Journal:  Nutrients       Date:  2020-10-22       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.